| 摘要 |
A medicinal new chemical entity is created when a targeted nanocarrier is combined with a PRDM gene- or protein-modulating agent. The present invention comprises a therapeutic agent comprising a nanocarrier labeled with one or more cell- or tissue-targeting moieties, which can deliver a therapeutic payload that modulates the activity of one or more PRDM genes or proteins or associated genes or proteins (e.g., the PRDM14 gene or protein). Nanocarriers incorporating the payload (e.g., a PRDM gene- or protein-modulating agent) and the targeting moieties are assembled. The compound is next administered to an animal (e.g., a human) with a disease or malady associated with the gene or a protein or other endogenous substance contributing to the disease process (e.g., cancer, a proliferative disease or other genetic disorder) so as to bring about a therapeutic effect. |
